Actively Recruiting
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Led by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Updated on 2026-04-08
40
Participants Needed
2
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
CONDITIONS
Official Title
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Histologically confirmed diagnosis of one of the following solid tumors: small cell lung cancer, high-grade neuroendocrine or small cell carcinomas of non-lung origin, non-small cell lung cancer, prostate cancer, ovarian cancer, renal carcinoma (clear and non-clear cell), head and neck squamous cell carcinoma, hepatic cancer, gastric cancer, or triple-negative breast cancer
- Disease that has progressed, relapsed, or intolerance to at least one prior standard systemic therapy for the underlying malignancy
- Measurable disease according to RECIST version 1.1
- Age 18 years or older
You will not qualify if you...
- Any medical or psychiatric condition that could compromise safety or ability to participate, as judged by the investigator
- Symptomatic brain metastases, leptomeningeal metastases, or spinal cord compression due to disease; brain metastases must be stable, off corticosteroids and anticonvulsants for at least 1 month, and not require specific brain metastasis intervention
- Active and clinically significant infection requiring systemic antibacterial, antiviral, or antifungal therapy within 7 days before the first dose
- Significant cardiac abnormalities
- Major surgery within 28 days before starting study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
START Dallas
Fort Worth, Texas, United States, 76104
Actively Recruiting
2
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
Research Team
E
Exscientia AI Ltd.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here